newsfilter
← Earnings
Earnings Releases·

Autolus Therapeutics — Third Quarter 2026 Earnings Summary

  • Net product revenue for Q3 2026 reached $41.2 million, a 95% year-over-year increase, while total nine-month revenue rose to $113.1 million; gross margin improved to 57% in Q3 2026 from a negative margin in the prior year period.
  • Full-year 2026 AUCATZYL net product revenue guidance is raised to at or exceeding the previous upper end of $150 million, supported by $100 million in proceeds from the Perceptive credit facility that extends cash runway into Q2 2028.
  • Clinical pipeline progress includes upcoming data reports for the ALARIC trial (ASH, Dec 2026), updated CARLYSLE trial data (ACR, Nov 2026), and the FDA's RMAT designation for obe-cel in SLE and LN; BOBCAT Phase 1 data presentation for progressive MS is rescheduled to Oct 2027 to ensure 12-month follow-up.
  • Operating expenses saw R&D increase to $30.9 million and SG&A decrease to $35.9 million in Q3 2026, resulting in a reduced net loss of $55.1 million compared to $79.1 million in the same period last year.
Company
AUTOLUS THERAPEUTICS PLC
Sector
Healthcare
Industry
Biotechnology